Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorPrograma d'Harmonització Farmacoterapèutica
dc.date.accessioned2021-10-19T11:36:12Z
dc.date.available2021-10-19T11:36:12Z
dc.date.issued2021-04-07
dc.identifier.citationPrograma d'Harmonització Farmacoterapèutica. Lanadelumab i l’inhibidor de la C1 esterasa d’administració subcutània per a la profilaxi a llarg termini de l’angioedema hereditari. Barcelona: Servei Català de la Salut; 2021.
dc.identifier.urihttps://hdl.handle.net/11351/6413
dc.descriptionLanadelumab; C1 Inhibitor; Hereditary Angioedema; Prophylaxis
dc.description.abstractHereditary angioedema (AEH) is a rare disease of autosomal dominant inheritance characterized by recurrent and unpredictable episodes of subcutaneous or submucosal edema, non-urticarial or pruritic, affecting the skin, upper airway, and / or gastrointestinal tract. The frequency of attacks can range from weekly to one or two episodes a year, and the presentation can be different between family members. Most attacks affect only one location, although they can affect multiple locations at once. Gastrointestinal attacks usually occur in most patients and are usually painful and debilitating. Its diagnosis can be complicated due to the similarity of the presentation with other gastrointestinal disorders. Laryngeal edemas usually appear in half of patients, but are rarely recurrent. These attacks can compromise the respiratory tract and life of patients, especially in children. In general, episodes are usually self-limiting and disappear after 48-72 hours, but can last up to 2-5 days.
dc.language.isocat
dc.publisherServei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectTracte gastrointestinal - Malalties
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectMedicaments - Assaigs clínics
dc.subject.meshAngioedemas, Hereditary
dc.subject.mesh/drug therapy
dc.subject.meshDrug Evaluation
dc.titleLanadelumab i l’inhibidor de la C1 esterasa d’administració subcutània per a la profilaxi a llarg termini de l’angioedema hereditari
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsangioedemas hereditarios
dc.subject.decs/farmacoterapia
dc.subject.decsevaluación de medicamentos
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record